0000899243-19-014037.txt : 20190517
0000899243-19-014037.hdr.sgml : 20190517
20190517182722
ACCESSION NUMBER: 0000899243-19-014037
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190516
FILED AS OF DATE: 20190517
DATE AS OF CHANGE: 20190517
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Wolchko J Scott
CENTRAL INDEX KEY: 0001586893
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36076
FILM NUMBER: 19837175
MAIL ADDRESS:
STREET 1: C/O FATE THERAPEUTICS, INC.
STREET 2: 3535 GENERAL ATOMICS COURT, SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: FATE THERAPEUTICS INC
CENTRAL INDEX KEY: 0001434316
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3535 GENERAL ATOMICS COURT
STREET 2: SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858.875.1803
MAIL ADDRESS:
STREET 1: 3535 GENERAL ATOMICS COURT
STREET 2: SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-05-16
0
0001434316
FATE THERAPEUTICS INC
FATE
0001586893
Wolchko J Scott
C/O FATE THERAPEUTICS, INC.;
3535 GENERAL ATOMICS COURT #200
SAN DIEGO
CA
92121
1
1
0
0
President and CEO
Common Stock
2019-05-16
4
M
0
14335
1.63
A
389216
D
Common Stock
2019-05-16
4
S
0
2298
18.464
D
386918
D
Common Stock
2019-05-16
4
S
0
12037
19.5442
D
374881
D
Stock Option (right to buy)
1.63
2019-05-16
4
M
0
14335
D
2022-02-08
Common Stock
14335
0
D
This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 20, 2018.
Represents the weighted average sale price of the shares sold ranging from $18.24 to $19.22 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.
Represents the weighted average sale price of the shares sold ranging from $19.24 to $19.91 per share. The Reporting person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.
The shares subject to this option became fully vested and exercisable on October 4, 2015.
Not applicable.
/s/ Cindy R. Tahl, as Attorney-in-Fact
2019-05-17